Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized multicenter study of LP-003 injection in wheat allergy
CTR20263401Phase 2Active
- Sponsor
- LongBio Pharma
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LP-003 in wheat allergy, wheat-dependent exercise-induced anaphylaxis (WDEIA), sponsored by LongBio Pharma. Started Sep 2026; status: active.
02
Drugs
LP-003
03
Conditions
wheat allergywheat-dependent exercise-induced anaphylaxis (WDEIA)
Beyond the preview
Go deeper on CTR20263401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263401.